<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Terapia celular > DA - CIMA - Oncología - Terapia celular - Artículos de Revista >

Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia
Authors: Roman-Gomez, J. (José)
Jimenez-Velasco, A. (A.)
Aguirre, X. (Xavier)
Castillejo, J.A. (J.A.)
Navarro, G. (Germán)
San-Jose, E. (Edurne)
Garate, L. (Leire)
Cordeu, L. (Lucía)
Cervantes, F. (F.)
Prosper, F. (Felipe)
Heiniger, A. (A.)
Torres, A. (Antonio)
Keywords: LINE1
Issue Date: 2007
Publisher: Elsevier
Publisher version:
ISSN: 0145-2126
Citation: Román-Gómez, J., Jiménez-Velasco, A., Agirre, X., Castillejo, J. A. et al. Leukemia Research 2007; 31 (11): 1521-1528
Repetitive elements are heavily methylated in normal tissues, but hypomethylated in malignant tissues, driving the global genomic hypomethylation found in cancer. This hypomethylation results in chromosomal instability, a well-characterized feature of the advanced phases of chronic myeloid leukemia (CML). We investigated methylation changes of DNA repetitive elements (LINE1, Alu, Satellite-alpha and Satellite-2) during the progression of CML from chronic phase (CP) to blast crisis (BC). CP-CML samples were significantly more hypomethylated for all repetitive sequences compared with normal samples. Furthermore, a more profound level of hypomethylation was observed among BC samples compared with CP samples. Our data suggest that repetitive DNA hypomethylation are closely associated with CML progression.
Permanent link:
Appears in Collections:DA - CIMA - Oncología - Síndromes mieloproliferativos - Artículos de Revista
DA - CIMA - Oncología - Terapia celular - Artículos de Revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Files in This Item:

There are no files associated with this item.

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.